What are the indications, appropriate stent type, sizing, and procedural steps for bronchial stenting in patients with central airway obstruction?

Bronchial Stenting

Bronchial stenting should be reserved as a last-line intervention after other therapeutic bronchoscopic and systemic treatments have failed in patients with symptomatic central airway obstruction (CAO). 1

Indications for Stenting

Stent placement is indicated when:

• Other therapeutic modalities have been exhausted, including tumor/tissue excision, ablation, dilation, and systemic therapies (chemotherapy, radiation) 1
• The underlying disorder is feasible for stenting (anatomically appropriate)
• Patient has symptomatic CAO defined as ≥50% occlusion of the trachea, mainstem bronchi, bronchus intermedius, or lobar bronchi 1

Common clinical scenarios include:

• Malignant extrinsic compression from lung cancer or metastatic disease 2, 3
• Postintubation/tracheostomy tracheal stenosis (benign) 1
• Tracheoesophageal or bronchopleural fistulas requiring covered stents 4
• Tracheobronchomalacia after failed conservative management 5

Critical Caveat

The 2025 CHEST guidelines emphasize stenting only when other treatments fail because stents carry significant complication risks requiring ongoing surveillance and reintervention 1. This represents a conservative, evidence-based approach prioritizing less invasive options first.

Stent Type Selection

Silicone Stents

Preferred for benign disease and situations requiring future removal 2, 6

Advantages:

• Easily repositioned and removed 2
• Lower risk of tissue ingrowth
• Suitable for temporary airway support

Disadvantages:

• Require rigid bronchoscopy for placement 2
• Higher migration rates 6
• More frequent need for repositioning

Metallic Stents (Nitinol)

Preferred for malignant disease in palliative settings 2, 6

Advantages:

• Can be placed via flexible bronchoscopy
• Better radial force maintaining patency under external compression 2
• Lower dislocation rates compared to silicone 6

Disadvantages:

• Difficult or impossible to remove once epithelialized 6
• Risk of granulation tissue formation, especially at proximal ends 6
• Should be avoided in benign disease or curative situations 6

Covered vs. Uncovered

• Covered stents: For fistulas (tracheoesophageal, bronchopleural) or to prevent tumor ingrowth 4
• Uncovered stents: Better incorporation but higher tumor ingrowth risk

Decision Algorithm:

1. Benign stenosis → Silicone stent (removable)
2. Malignant stenosis, curative intent possible → Silicone stent (removable if surgery later)
3. Malignant stenosis, palliative only → Nitinol metallic stent (superior mechanics, removal not needed) 6

Stent Sizing

Critical sizing principles:

• Stents must extend minimum 5mm beyond the stenotic area on both ends to prevent luminal narrowing when loads are applied 2
• Measure airway diameter at stenosis and proximal/distal normal segments using CT imaging 5
• Consider reinforced ends to prevent compression 2
• For Y-stents at carina: customize based on individual anatomy 7

Measurement approach:

• Obtain thin-slice CT chest with multiplanar reconstructions
• Measure tracheal/bronchial diameter at stenosis
• Measure normal proximal and distal airway diameters
• Select stent diameter matching normal airway (typically 10-20mm for trachea, 8-12mm for main bronchi)
• Ensure length covers stenosis plus 5mm margins 2

Procedural Steps

Pre-Procedure

1. Comprehensive evaluation 1:

   • CT chest with thin cuts to define stenosis location, length, degree
   • Flexible bronchoscopy with video documentation
   • Pulmonary function tests if feasible
   • Multidisciplinary team review (pulmonology, thoracic surgery, interventional radiology) 8

2. Anesthesia planning:

   • General anesthesia or deep sedation preferred over moderate sedation 1
   • Jet ventilation or controlled/spontaneous assisted ventilation for rigid bronchoscopy 1

Procedure

1. Rigid bronchoscopy preferred over flexible for therapeutic interventions 1

2. Airway preparation sequence:

   • Tumor/tissue debulking if endobronchial disease present (mechanical debridement, laser, electrocautery) 1
   • Airway dilation if stenosis present (balloon or rigid dilators) 1
   • Hemostasis achieved before stent placement

3. Stent deployment:

   • Silicone stents: Require rigid bronchoscopy, deployed using pusher technique
   • Metallic stents: Can use flexible bronchoscopy with fluoroscopic guidance
   • Y-stents: Single guidewire technique through left bronchus simplifies placement (38 vs 51 minutes procedure time) 7
   • Confirm position with bronchoscopy and fluoroscopy
   • Document final position with imaging

Post-Procedure Surveillance

Either routine surveillance bronchoscopy OR symptom-driven bronchoscopy is acceptable 1

Practical approach:

• Initial bronchoscopy at 4-6 weeks to assess stent position and complications
• Subsequent surveillance every 3-6 months for first year
• Then symptom-driven if stable
• 41% of patients require multiple procedures to maintain satisfactory airway 3

Common Complications and Management

Early complications:

• Migration/dislocation (more common with silicone) 6, 9
  • Management: Repositioning or fixation with clips/sutures 9
• Mucus plugging
  • Management: Aggressive pulmonary toilet, bronchoscopy

Late complications:

• Granulation tissue formation (especially metallic stents at ends) 6
  • Management: Laser ablation, cryotherapy, or stent revision
• Stent fracture (metallic)
• Tumor/tissue ingrowth (uncovered metallic)

Critical pitfall: Metallic stents in benign disease create permanent problems—removal after epithelialization requires complex surgery 6. Always use silicone for benign stenosis.

Emerging Technologies

Biodegradable stents show promise for benign stenosis, offering personalized treatment duration (median 10.6 months) with lower complication rates than conventional stents 9. However, these remain investigational and not yet standard of care.